Tranzyme posts postive data for gastroparesis drug

Research Triangle Park, NC-based Tranzyme Pharma said its drug TZP-101 for gastroparesis was effective in a mid-stage trial. Gastroparesis is an inability of the stomach to empty food efficiently, especially in patients with diabetes mellitus. The trial results indicate TZP-101 is safe highly effective in improving multiple symptoms associated with gastroparesis. Given intravenously for four days, the drug induced an acute and sustained reduction of symptoms

"These results are consistent with the potent prokinetic properties of TZP-101 and complement our previously reported successful Phase II study with TZP-101 for the management of postoperative ileus," said Gordana Kosutic, vice president, clinical and regulatory affairs. Tranzyme plans to initiate a Phase III study of the drug. Back in October CEO Vipin Garg indicated that Tranzyme would either look to partner TZP-101, raise $60 million or sell the company.

- take a look at Tranzyme's release

Related Article:
Tranzyme Pharma plots its next financing move
Tranzyme's $20M round takes lead therapy to Phase III (2007)